Biotech start-up Normunity, Inc. has exited stealth with a $65 million Series A to create a new class of medicines that target novel I-O mechanisms, which free the body’s normal immunity against ...
2022 wasn't exactly a banner year for first-person shooters, but it did bring us Hyper Demon. Like its predecessor Devil Daggers, Hyper Demon boasted a trippy art-style and emphasised fast-paced, high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback